Pegylated interferon for acute hepatitis C

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Simin, Marija ^a   Myers, R P ^b   Stimac, D ^b   Gluud, C ^b  

^a Rigshospitalet   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON;

CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; EMBASE; HEPATITIS C; HUMAN; MEDLINE; METHODOLOGY; REVIEW; RISK BENEFIT ANALYSIS; VIRUS TRANSMISSION;

EID: 44949110215     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006392     Document Type: Review

References (33)

1. Algranati 1999 Algranati NE, Sy S, Modi M. A branchedmethoxy 40 kDa polyethylene glycol moiety optimizes the pharmacokinetics of peginterferon alpha-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC) [abstract]. Hepatology 1999;30(4 Pt. 2):190A.
2. Als-Nielsen 2004 Als-Nielsen B, Gluud LL, Gluud C. Methodological quality and treatments effects in randomised trials - a review of six emperical studies (abstract O-072). 12th Cochrane Colloquium, Ottawa, Canada 2004. www.cochrane.org/colloquia/abstracts/ottawa/ (accessed March 11, 2005).
3. Benvegnu 2001 Benvegnu L, Alberti A. Patterns of hepatocellular carcinoma development in hepatitis B virus- and hepatitis C virus-related cirrhosis. Antiviral Research 2001;52:199-207.
4. Bradburn 2006 Bradburn MJ, Deeks JJ, Berlin JA, Localio RA. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine 2006; (Epub ahead of print):(http://www3.interscience.wiley.com/cgi-bin/fulltext/112556369/ PDFSTART).
5. Brok 2005 Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C. The Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD005445. DOI:10.1002/14651858.CD005445.
6. Davis 1999 Davis GL. Hepatitis C virus genotypes and quasispecies. American Journal of Medicine 1999;107(6B):21S-26S.
7. DeMets 1987 DeMets DL. Methods of combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
8. DerSimonian 1986 DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
9. Egger 1997 Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
10. Fattovich 2002 Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E, the European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. American Journal of Gastroenterology 2002;97(11):2886-95.
11. Gerlach 2003 Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-8.
12. Gluud 2006 Gluud C, Als-Nielsen B, D'Amico G, Fingerhut A, Gluud LL, Khan S, et al. Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2006, Issue 3. Art. No.: LIVER.
13. Higgins 2002 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
14. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & sons, Ltd.
15. Hollis 1999 Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ (Clinical Research Ed.) 1999;319:670-4.
16. Kamal 2006 Kamal SM, Moustafa KN, Chen J, Fehr J, Moneim AA, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: A randomized trial. Hepatology 2006;43(5):923-31.
17. Kjaergard 2001 Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11): 982-9.
18. Lavanchy 1999 Lavanchy D. Hepatitis C: public health strategies. Journal of Hepatology 1999;31(Suppl 1):146-51.
19. Moher 1998 Moher D, PhamB, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
20. Myers 2001 Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al. Interferon for acute hepatitis C. The Cochrane Database of Systematic Reviews 2001, Issue 4 Art. No.: CD000369. DOI:10.1002/14651858. CD000369.
21. OPTN 2002 United Network for Organ Sharing. Organ Procurement and Transplant Network (OPTN) data as of March 1, 2002. Transplants by diagnosis: January 1991 to November 2001. www.unos.org (accessed January 10, 2003).
22. Pawlotsky 2000 Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quanitification. Hepatology 2000;32(3):654-9.
23. Pawlotsky 2002 Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002;36(5 Suppl 1):S65-S73.
24. Poynard 1997 Poynard T, Bedossa P, Opolon P for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349(9055):825-32.
25. RevMan 2003 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
26. Rosenberg 2001 Rosenberg S. Recent advances in the molecular biology of hepatitis C virus. Journal of Molecular Biology 2001;313:451-64.
27. Roudot-Thoraval 1997 Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D, the Study group for the prevalence and the epidemiology of hepatitis C virus. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6664 patients. Hepatology 1997;26(2):485-90.
28. Royle 2003 Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
29. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions ofmethodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408- 12.
30. Shakil 1995 Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Annals of Internal Medicine 1995;123(5): 330-7.
31. Simin 2007 Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C. The Cochrane Library 2007, Issue 2 (submitted for publication).
32. Strader 2004 Strader DB, Wright T, Thomas LD, Seeff LB. AASLD practice guideline: diagnosis, managment, and treatment of hepatitis C. Hepatology 2004;39(4):1147-71.
33. WHO 2000 WHO.Hepatitis C. www.who.int/mediacentre/factsheets/ fs164/en/ (accessed 15 November 2006).